Radiobiology data of melanoma cells after low-energy neutron irradiation and boron compound administration.


Journal

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
ISSN: 1872-9800
Titre abrégé: Appl Radiat Isot
Pays: England
ID NLM: 9306253

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 01 10 2019
revised: 11 12 2019
accepted: 21 04 2020
pubmed: 12 5 2020
medline: 11 8 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

The cold neutron beam at the PF1b line at the Institut Laue-Langevin (ILL), without fast neutrons and a low contribution of gamma rays, is a very suitable facility to measure cell damage following low-energy neutron irradiation. The biological damage associated with the thermal and the boron doses can be obtained in order to evaluate the relative biological effectiveness (RBE) for Boron Neutron Capture Therapy. Three different experiments were carried out on the A375 melanoma cell line: the first one in a hospital LINAC, to obtain the reference radiation data, and the other two at the ILL, in which the damage to cells with and without boron compounds added was measured.

Identifiants

pubmed: 32392166
pii: S0969-8043(20)30334-1
doi: 10.1016/j.apradiso.2020.109205
pii:
doi:

Substances chimiques

Boron Compounds 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109205

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

María Pedrosa-Rivera (M)

Institut Laue-Langevin, 71 Avenue des Martyrs, 38042, Grenoble, Cedex 9, France; Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias, Universidad de Granada, 18071, Granada, Spain. Electronic address: mpedrosa@ugr.es.

M José Ruiz-Magaña (MJ)

Departamento de Bioquímica y Biología Molecular III e Inmunología, Facultad de Medicina, Universidad de Granada, 18071, Granada, Spain.

Patricia Álvarez (P)

Departamento de Bioquímica y Biología Molecular III e Inmunología, Facultad de Medicina, Universidad de Granada, 18071, Granada, Spain.

Ignacio Porras (I)

Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias, Universidad de Granada, 18071, Granada, Spain.

Javier Praena (J)

Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias, Universidad de Granada, 18071, Granada, Spain.

Manuel P Sabariego (MP)

Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias, Universidad de Granada, 18071, Granada, Spain.

Ulli Köster (U)

Institut Laue-Langevin, 71 Avenue des Martyrs, 38042, Grenoble, Cedex 9, France.

Michael Haertlein (M)

Institut Laue-Langevin, 71 Avenue des Martyrs, 38042, Grenoble, Cedex 9, France.

V Trevor Forsyth (VT)

Institut Laue-Langevin, 71 Avenue des Martyrs, 38042, Grenoble, Cedex 9, France; Faculty of Natural Sciences, Keele University, Staffordshire, ST5 5BG, UK.

Torsten Soldner (T)

Institut Laue-Langevin, 71 Avenue des Martyrs, 38042, Grenoble, Cedex 9, France.

José C Ramírez (JC)

Servicio de Radiofísica y Protección Radiológica, Hospital Universitario Virgen de las Nieves, Avda Fuerzas Armadas 2, 18014, Granada, Spain.

Clara Jover (C)

Servicio de Radiofísica y Protección Radiológica, Hospital Universitario Virgen de las Nieves, Avda Fuerzas Armadas 2, 18014, Granada, Spain.

Daniel Jimena (D)

Servicio de Radiofísica y Protección Radiológica, Hospital Universitario Virgen de las Nieves, Avda Fuerzas Armadas 2, 18014, Granada, Spain.

Juan L Osorio (JL)

Servicio de Radiofísica y Protección Radiológica, Hospital Universitario Virgen de las Nieves, Avda Fuerzas Armadas 2, 18014, Granada, Spain.

Ian Postuma (I)

Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, via A. Bassi 6, 27100, Pavia, Italy.

Carmen Ruiz-Ruiz (C)

Departamento de Bioquímica y Biología Molecular III e Inmunología, Facultad de Medicina, Universidad de Granada, 18071, Granada, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH